22NW LP Buys New Shares in Keros Therapeutics, Inc. $KROS

Key Points

• 22NW LP has acquired a new stake in Keros Therapeutics, buying 179,000 shares valued at approximately $1.8 million, making it the fund's 16th largest holding.
• Recent analysts' ratings for Keros Therapeutics show mixed forecasts, with Bank of America downgrading the stock from "buy" to "neutral" and lowering the target price from $32 to $18.
• Keros Therapeutics reported a significant year-over-year revenue increase of 49002.7%, with a quarterly loss of ($0.76) earnings per share, beating the consensus estimate.

22NW LP bought a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 179,000 shares of the company's stock, valued at approximately $1,824,000. Keros Therapeutics makes up about 1.4% of 22NW LP's portfolio, making the stock its 16th biggest position. 22NW LP owned approximately 0.44% of Keros Therapeutics as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Two Sigma Investments LP increased its holdings in Keros Therapeutics by 226.1% during the 4th quarter. Two Sigma Investments LP now owns 33,664 shares of the company's stock valued at $533,000 after acquiring an additional 23,342 shares in the last quarter. Darwin Global Management Ltd. increased its holdings in Keros Therapeutics by 10.7% during the 4th quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company's stock valued at $26,707,000 after acquiring an additional 163,403 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in Keros Therapeutics during the 4th quarter valued at about $730,000. Barclays PLC increased its holdings in Keros Therapeutics by 79.2% during the 4th quarter. Barclays PLC now owns 107,542 shares of the company's stock valued at $1,703,000 after acquiring an additional 47,528 shares in the last quarter. Finally, Tejara Capital Ltd purchased a new position in Keros Therapeutics during the 1st quarter valued at about $410,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on KROS. Wedbush restated a "neutral" rating and set a $15.00 target price on shares of Keros Therapeutics in a report on Friday, May 30th. Scotiabank dropped their target price on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a report on Monday, May 12th. Bank of America downgraded shares of Keros Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $32.00 to $18.00 in a report on Tuesday, June 10th. Finally, HC Wainwright lowered their price target on shares of Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a report on Friday, August 8th. Seven research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company's stock. Based on data from MarketBeat, Keros Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $30.00.

Keros Therapeutics Trading Down 1.7%

Shares of NASDAQ KROS traded down $0.26 during midday trading on Friday, reaching $15.00. 79,241 shares of the stock were exchanged, compared to its average volume of 959,020. The company has a market capitalization of $609.02 million, a P/E ratio of 48.21, a P/E/G ratio of 2.00 and a beta of 1.33. Keros Therapeutics, Inc. has a 52-week low of $9.12 and a 52-week high of $72.37. The stock has a 50 day moving average price of $14.16 and a 200-day moving average price of $13.10.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, topping analysts' consensus estimates of ($1.14) by $0.38. Keros Therapeutics had a net margin of 8.06% and a return on equity of 2.96%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $3.83 million. During the same period in the previous year, the firm posted ($1.25) earnings per share. The company's quarterly revenue was up 49002.7% compared to the same quarter last year. On average, analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.